TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair